Repligen (NASDAQ:RGEN – Get Free Report) updated its FY24 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $1.42-1.49 for the period, compared to the consensus estimate of $1.45. The company issued revenue guidance of $620-635 million, compared to the consensus revenue estimate of $636.53 million. Repligen also updated its FY 2024 guidance to 1.420-1.490 EPS.
Repligen Stock Up 12.0 %
RGEN stock traded up $16.52 during trading on Tuesday, reaching $154.52. 1,361,625 shares of the company traded hands, compared to its average volume of 621,315. The business has a 50 day simple moving average of $134.79 and a 200 day simple moving average of $166.21. Repligen has a 12 month low of $110.45 and a 12 month high of $211.13. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.24 and a current ratio of 6.35. The company has a market capitalization of $8.63 billion, a price-to-earnings ratio of 622.18, a price-to-earnings-growth ratio of 4.71 and a beta of 0.96.
Repligen (NASDAQ:RGEN – Get Free Report) last posted its earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.01). Repligen had a net margin of 2.44% and a return on equity of 3.95%. The company had revenue of $151.31 million during the quarter, compared to analysts’ expectations of $150.06 million. During the same quarter last year, the firm earned $0.64 EPS. Repligen’s revenue for the quarter was down 17.1% on a year-over-year basis. On average, equities research analysts anticipate that Repligen will post 1.46 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
View Our Latest Analysis on RGEN
Insider Transactions at Repligen
In related news, CEO Anthony Hunt sold 20,072 shares of Repligen stock in a transaction dated Tuesday, May 21st. The stock was sold at an average price of $168.26, for a total transaction of $3,377,314.72. Following the completion of the sale, the chief executive officer now owns 163,177 shares of the company’s stock, valued at $27,456,162.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Anthony Hunt sold 20,072 shares of Repligen stock in a transaction dated Tuesday, May 21st. The stock was sold at an average price of $168.26, for a total transaction of $3,377,314.72. Following the completion of the sale, the chief executive officer now owns 163,177 shares of the company’s stock, valued at $27,456,162.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Martin D. Madaus bought 1,615 shares of the firm’s stock in a transaction that occurred on Friday, June 14th. The shares were purchased at an average cost of $124.94 per share, with a total value of $201,778.10. Following the acquisition, the director now directly owns 4,613 shares of the company’s stock, valued at $576,348.22. The disclosure for this purchase can be found here. Insiders own 1.20% of the company’s stock.
About Repligen
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Featured Stories
- Five stocks we like better than Repligen
- Using the MarketBeat Dividend Yield Calculator
- AbbVie Analysts Lead the Stock Higher as Humira Worries Recede
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Harley-Davidson Stock Revs Up With Billion Dollar Buyback Program
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Cruise Line Stock Sinks Despite Beating EPS and Raised Guidance
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.